查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945890

瘧疾疫苗市場－全球產業規模、佔有率、趨勢、機會及預測（依疫苗類型、給藥途徑、地區及競爭格局分類，2021-2031年）

Malaria Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vaccine Type, By Route of Administration, By Region and Competition 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球瘧疾疫苗市場預計將經歷顯著成長，預計從 2025 年的 14.1 億美元成長到 2031 年的 38.4 億美元，複合年成長率達到 18.17%。

該領域專注於研發和推廣旨在賦予人體對瘧疾原蟲適應性免疫的生物製藥。推動該市場發展的關鍵因素在於降低高流行地區疾病負擔的緊迫性，以及國際衛生組織實施的強力的採購框架。這些結構性基礎提供了穩定的需求來源，使其不受瞬息萬變的技術趨勢影響，從而確保市場擴張植根於永續的公共衛生策略，而非曇花一現的研究趨勢。

市場概覽
預測期 2027-2031
市場規模：2025年 14.1億美元
市場規模：2031年 38.4億美元
複合年成長率：2026-2031年 18.17%
成長最快的細分市場 多抗原
最大的市場 北美洲

儘管有這些正面跡象，但市場仍面臨嚴峻挑戰，產能與全球龐大的需求之間存在巨大缺口，供應鏈瓶頸也常常阻礙疫苗及時送達偏遠地區。根據全球疫苗免疫聯盟（Gavi）的數據，2024年，超過1050萬劑瘧疾疫苗被採購並分發至17個瘧疾流行國家。這一數字凸顯了擴大生產設施的迫切需求，以及為充分滿足當前市場需求而面臨的巨大物流壓力。

市場促進因素

將瘧疾疫苗納入國家常規免疫規劃是市場成長的關鍵促進因素。這將使疫苗接種從有限的試點階段過渡到全國範圍的推廣，從而顯著擴大覆蓋人群。這項轉變需要穩健的供應鏈和政府對持續供應的堅定承諾。正如全球疫苗免疫聯盟（Gavi）2025年4月發布的報告《瘧疾消除疫苗接種》中所述，已有25個國家的疫苗接種資金獲得核准，這表明除最初的試點國家外，疫苗需求將大幅成長。為了支持這項廣泛的推廣，採購機構正在積極談判有利的商業條款，以在預算範圍內最大限度地擴大覆蓋範圍。聯合國兒童基金會於2025年11月宣布，新的供應協議將節省9,000萬美元，從而能夠採購數百萬劑額外的疫苗。

此外，主要國際組織增加的資金投入和採購承諾為製造商提供了擴大營運規模所需的財務穩定性。與受消費者購買力波動影響的民營市場不同，製藥業依賴持續的捐助資金來彌合低收入國家生產成本與消費者承受能力之間的差距。這種財務保障使藥物研發者能夠投資於長期產能擴張，而無需承擔市場風險。例如，全球疫苗免疫聯盟（Gavi）於2025年宣布計劃在2026年至2030年間向其瘧疾疫苗計畫投資超過11億美元，這是一項至關重要的舉措，旨在使生產規模與全球消除瘧疾的目標保持一致。

市場挑戰

全球瘧疾疫苗市場面臨的一大限制因素是產能有限與全球迫切需求之間的巨大不匹配。儘管國際需求旺盛，但生產所需的複雜生物製程阻礙了產量的快速成長，無法滿足激增的需求。這種不平衡導致潛在收益延遲，而產品供不應求也從根本上限制了疫苗的廣泛應用，因此無法顯著提升市場價值。

因此，供應鏈瓶頸和嚴格的生產限制迫使執行機構只能配給供應，而無法滿足全部市場需求。這種無法有效涵蓋全部潛在市場（TAM）的情況限制了產業的成長速度。據聯合國兒童基金會稱，2024年確保的RTS,S疫苗供應量僅為2023-2025年期間的約1800萬劑，遠低於目標國家的迫切需求。這些限制意味著實際市場規模小於預測模型所顯示的規模，成長仍然主要受物流可行性而非購買意願的驅動。

市場趨勢

新一代mRNA疫苗平台的開發代表著一項重要的技術轉捩點，它克服了傳統蛋白質製劑的療效限制。研發人員旨在利用這種擴充性的架構來靶向多種瘧原蟲階段，從而加速設計迭代並提高疫苗對複雜瘧疾原蟲的持久性。然而，向這些新型機制的過渡需要經過嚴格的監管審查，這是實驗性生物平台的典型特徵，並可能導致間歇性延誤。例如，Contagion Live在2025年3月報道稱，美國FDA已暫時中止了BioNTech公司mRNA候選疫苗BNT165e的I/II期臨床試驗。該試驗已招募了約180名受試者，凸顯了嚴格監管該技術的安全通訊協定的重要性。

同時，向疫情地區部署生產能力的趨勢正在重塑全球供應鏈，透過在疫情高負擔地區附近建立生產網路來實現這一目標。這一結構性趨勢旨在減少對跨洲集中式供應鏈的依賴，並降低成品進口帶來的物流風險。國際衛生組織正積極支持區域自主，透過資助基礎建設，使非洲國家能夠管理自身的衛生安全。正如世界衛生組織（世衛組織）2025年8月的一份報告所強調的，國際藥品採購機制（Unitaid）已承諾向一項旗艦項目提供約5000萬美元的資金，以加強非洲本地生產基本醫療診斷和治療產品的能力。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球瘧疾疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依疫苗類型（紅血球前期疫苗、紅血球期疫苗、多抗原疫苗、其他）
    • 依給藥途徑（肌肉注射、皮下注射、皮內注射、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美瘧疾疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲瘧疾疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區瘧疾疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲瘧疾疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲瘧疾疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球瘧疾疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline, Plc.
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Sanaria Inc.
  • Merck & Co.
  • Johnson & Johnson
  • Pfizer Inc.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • Moderna Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 14997

The Global Malaria Vaccine Market is projected to experience substantial growth, increasing from USD 1.41 Billion in 2025 to USD 3.84 Billion by 2031, achieving a CAGR of 18.17%. This sector focuses on the creation and distribution of biological preparations aimed at conferring acquired immunity against Plasmodium parasites. The primary forces driving this market are the critical imperative to reduce the disease burden in high-transmission areas and the strong procurement frameworks implemented by international health organizations. These structural pillars provide a consistent demand base independent of fleeting technological trends, ensuring that market expansion is rooted in enduring public health strategies rather than temporary research shifts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.41 Billion
Market Size 2031USD 3.84 Billion
CAGR 2026-203118.17%
Fastest Growing SegmentMulti-antigen
Largest MarketNorth America

Despite these positive indicators, the market confronts a significant hurdle regarding the disparity between manufacturing capacities and the immense scale of global demand, as supply chain constraints frequently impede the timely delivery of vaccines to remote regions. Data from Gavi, the Vaccine Alliance, indicates that in 2024, over 10.5 million malaria vaccine doses were procured and distributed to 17 endemic nations. This figure highlights the intense logistical pressures and the urgent need for expanded production facilities to adequately serve the requirements of the current market landscape.

Market Driver

The incorporation of malaria vaccines into National Routine Immunization Schedules serves as the primary engine for market growth, transitioning the sector from restricted pilot schemes to broad national adoption. This shift vastly expands the addressable patient population, requiring resilient supply chains and steadfast government dedication to consistent delivery. As noted in Gavi's April 2025 report, 'Rolling out vaccines to beat malaria together,' funding was approved for 25 countries to introduce the vaccine, signaling a rapid surge in demand beyond the initial pilot nations. To support this broad rollout, procurement agencies are actively negotiating beneficial commercial terms to maximize reach within budgetary limits, with UNICEF announcing in November 2025 that a new supply agreement secured US$ 90 million in savings to purchase millions of additional doses.

Furthermore, increased funding and procurement pledges from major international bodies provide the necessary financial stability for manufacturers to scale their operations. Distinct from private markets influenced by variable consumer spending power, this sector depends on sustained donor capital to reconcile the difference between production costs and affordability in low-income nations. These financial assurances enable pharmaceutical developers to invest in long-term capacity expansion without facing unmitigated market risks. For instance, Gavi announced in 2025 a plan to invest over US$ 1.1 billion in malaria vaccination programs during the 2026-2030 period, a commitment essential for aligning manufacturing output with global disease eradication goals.

Market Challenge

A critical constraint on the Global Malaria Vaccine Market is the disconnect between limited manufacturing capabilities and the immediate magnitude of global demand. Although international mandates drive substantial order volumes, the intricate biological processes required for production prevent manufacturers from rapidly increasing output to match this surge in interest. This imbalance creates a scenario where potential revenue is postponed, and the widespread adoption necessary for significant market valuation is physically restricted by product unavailability.

Consequently, supply chain bottlenecks and rigid production ceilings compel implementing organizations to ration distributions rather than fulfilling the total market potential. This inability to effectively service the total addressable market limits the industry's growth rate. According to UNICEF, the secured supply of the RTS,S vaccine in 2024 was restricted to approximately 18 million doses for the 2023-2025 period, a volume far below the immediate needs of eligible nations. Such constraints ensure that the actual market size remains smaller than demand models predict, with growth dictated more by logistical feasibility than by buyer intent.

Market Trends

The development of Next-Generation mRNA Vaccine Platforms marks a significant technological shift aimed at overcoming the efficacy limitations of earlier protein-based formulations. Developers are utilizing this scalable architecture to target multiple parasite stages, aiming to accelerate design iterations and enhance durability against the complex Plasmodium pathogen. However, the move to these novel mechanisms involves rigorous regulatory scrutiny typical for experimental biological platforms, which can lead to intermittent delays. For example, Contagion Live reported in March 2025 that the US FDA paused BioNTech's Phase I/II trial of the mRNA candidate BNT165e, which had enrolled nearly 180 participants, underscoring the strict safety protocols governing this technology.

Simultaneously, the localization of manufacturing capabilities in endemic regions is reshaping the global supply landscape by positioning production closer to high-burden populations. This structural trend seeks to reduce reliance on centralized intercontinental supply chains, thereby mitigating the logistical risks associated with importing finished doses. International health agencies are actively supporting regional autonomy by funding infrastructure that enables African nations to manage their own health security. As highlighted in an August 2025 World Health Organization report, Unitaid pledged nearly US$ 50 million to flagship programs designed to boost Africa's capacity to locally produce essential medical diagnostics and therapeutics.

Key Market Players

  • GlaxoSmithKline, Plc.
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Sanaria Inc.
  • Merck & Co.
  • Johnson & Johnson
  • Pfizer Inc.
  • Serum Institute of India Private Limited
  • Bharat Biotech International Limited
  • Moderna Inc

Report Scope

In this report, the Global Malaria Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Vaccine Market, By Vaccine Type

  • Pre-Erythrocytic
  • Erythrocytic
  • Multi-antigen
  • Others

Malaria Vaccine Market, By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Intradermal
  • Others

Malaria Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Vaccine Market.

Available Customizations:

Global Malaria Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Vaccine Type (Pre-Erythrocytic, Erythrocytic, Multi-antigen, Others)
    • 5.2.2. By Route of Administration (Intramuscular, Subcutaneous, Intradermal, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Malaria Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Vaccine Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malaria Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Vaccine Type
        • 6.3.1.2.2. By Route of Administration
    • 6.3.2. Canada Malaria Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Vaccine Type
        • 6.3.2.2.2. By Route of Administration
    • 6.3.3. Mexico Malaria Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Vaccine Type
        • 6.3.3.2.2. By Route of Administration

7. Europe Malaria Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Vaccine Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malaria Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Vaccine Type
        • 7.3.1.2.2. By Route of Administration
    • 7.3.2. France Malaria Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Vaccine Type
        • 7.3.2.2.2. By Route of Administration
    • 7.3.3. United Kingdom Malaria Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Vaccine Type
        • 7.3.3.2.2. By Route of Administration
    • 7.3.4. Italy Malaria Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Vaccine Type
        • 7.3.4.2.2. By Route of Administration
    • 7.3.5. Spain Malaria Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Vaccine Type
        • 7.3.5.2.2. By Route of Administration

8. Asia Pacific Malaria Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Vaccine Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malaria Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Vaccine Type
        • 8.3.1.2.2. By Route of Administration
    • 8.3.2. India Malaria Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Vaccine Type
        • 8.3.2.2.2. By Route of Administration
    • 8.3.3. Japan Malaria Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Vaccine Type
        • 8.3.3.2.2. By Route of Administration
    • 8.3.4. South Korea Malaria Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Vaccine Type
        • 8.3.4.2.2. By Route of Administration
    • 8.3.5. Australia Malaria Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Vaccine Type
        • 8.3.5.2.2. By Route of Administration

9. Middle East & Africa Malaria Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Vaccine Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malaria Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Vaccine Type
        • 9.3.1.2.2. By Route of Administration
    • 9.3.2. UAE Malaria Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Vaccine Type
        • 9.3.2.2.2. By Route of Administration
    • 9.3.3. South Africa Malaria Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Vaccine Type
        • 9.3.3.2.2. By Route of Administration

10. South America Malaria Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Vaccine Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Vaccine Type
        • 10.3.1.2.2. By Route of Administration
    • 10.3.2. Colombia Malaria Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Vaccine Type
        • 10.3.2.2.2. By Route of Administration
    • 10.3.3. Argentina Malaria Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Vaccine Type
        • 10.3.3.2.2. By Route of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malaria Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline, Plc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Takeda Pharmaceutical Company
  • 15.4. Sanaria Inc.
  • 15.5. Merck & Co.
  • 15.6. Johnson & Johnson
  • 15.7. Pfizer Inc.
  • 15.8. Serum Institute of India Private Limited
  • 15.9. Bharat Biotech International Limited
  • 15.10. Moderna Inc

16. Strategic Recommendations

17. About Us & Disclaimer